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Abstract
Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality in developed counties. It is estimated that
60 million Americans have LDL-C levels > 160 mg/dl. Only about 1/3 of these patients meet treated LDL cholesterol goals of < 70
mg/dl indicating a need for greater control. High dose statins have been the mainstay in treatment of dyslipidemia, however, up to
20% of patients are statin intolerant indicating a need for secondary treatment strategies. This lead to the development of monoclonal
antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 inhibitors result in decreased destruction of
the low-density lipoprotein receptor (LDL-R) which leads to an increase in the transport of LDL-C to its destruction effectively
reducing LDL-C levels in the blood. The purpose of this study is to analyze the literature available on the efficacy and safety of new
PCSK9 inhibitors. The results of this literature review indicated that PCSK9 inhibitors effectively lowered LDL-C by an average of
approximately 50%. The evidence reviewed by this analysis indicate that 70% of patients treated with PCSK9 inhibitors met LDL-C
goals. The findings also indicate that the side effects associated with this new class of medications are comparable to current side
effects seen with traditional cholesterol lowering agents. The largest side effect seen in up to 10% of patients were injection site
reactions and did not require discontinuation of the medication. The results of this analysis indicate that PCSK9 inhibitors may be of
benefit in patients who are statin intolerant, do not meet LDL-C goals on traditional statin therapy or have familial
hypercholesterolemia. Education in use of injectables, cost and insurance coverage and dosing schedule are likely to be areas of
continued research and may affect use of this new class of cholesterol lowering agents.

Introduction
•

Elevated levels of low-density lipoprotein cholesterol (LDLC), have been implicated in increased risk of major
cardiovascular events making the reduction of LDL-C a major
goal in the reduction of atherosclerotic cardiovascular disease.

Statement of the Problem
• Even with high dose statin therapy, only one-third of patients
reach goal LDL-C levels <70 mg/dl.
• Approximately 10-20%, of patients are unable to tolerate statins
due to significant muscle related adverse reactions.
• The main agent utilized in patients who are statin intolerant is
ezetimibe, which at its maximum, has the ability to lower
cholesterol by 18% (Sullivan, 2012) leaving many patients
struggling with elevated cholesterol levels and therefore
increased risk for cardiovascular events.
• This has led to the development of a new class of therapeutics,
the proprotein convertase subtilisin/kexin type 9 inhibitors
(PCSK9 inhibitors).
• Current Phase 1-3 trials are investigating the pathophysiology,
efficacy, side effects, dosing and areas for future research of this
new class of cholesterol lowering agents.

Research Question
In patients with hyperlipidemia that is not well controlled with
traditional statin therapy, do PCSK9 inhibitors bring LDL
cholesterol closer to goal than placebo?
In Patients Treated with PCSK9 Inhibitors, are Side Effects More
Severe than Traditional Statin Therapy, Ezetimibe or Placebo?
What Does Current Literature Say About Dosing and Future
Research?

Literature Review
• The goal of the PCSK9 inhibitors is to decrease the amount of
PCSK9 that is available to bind to the LDL-R allowing the
LDL-R to bind to and eliminate more LDL-C, effectively
decreasing the level of serum LDL-C.
• Ballantyne et al demonstrated a decrease in total cholesterol of
27.6-53.4 mg/dl, a 27-53% reduction from baseline when
assessing efficacy in bi-monthly and monthly injections of
PCSK9 inhibitors.
• Sullivan et al demonstrated a 41-63% decrease in LDL-C
treated with PCSK9 inhibitors compared to a 15% decrease in
those treated with Ezetimibe.
• Raal et al looked at the effect of PCSK9 inhibitors in group
treated at bi-monthly and monthly intervals. They showed a
59.2% reduction in LDL-C in the bi-monthly group and a
61.3% reduction in the group treated monthly.
• In a study by Robinson et al, a 61.0% reduction in LDL-C was
demonstrated in the PCSK9 inhibitor group compared to a
0.8% increase in LDL-C in the placebo group.
• Koren et al showed that 70% of patients in the PCSK9
inhibitors group met their LDL-C goal compared to only 1%
of the placebo group and 2% of the ezetimibe group
• Stroes and Roth also demonstrated significant reductions in
LDL-C, with the majority of patients meeting their LDL-C
goals.
• Ballantyne, indicated that the most prevalent side effect noted
by patients treated with PCSK9 inhibitors was injection site
reactions ranging in prevalence from 4-10% of patients.
• Additional side effects reported in a small percentage of
patients included nasopharyngitis, fatigue, nausea, diarrhea
and myalgias.

Discussion
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• Due to patient inexperience with injectable agents, it will
be imperative that providers provide an option for
education to allow patients to become comfortable and
trained in the use of injectable agents in order to decrease
injection site reactions.

Applicability to Clinical Practice
• Research has demonstrated that PCSK9 inhibitors are highly
specific to their target, do not penetrate the blood brain barrier,
have a long serum half-life, and limited adverse side effects
making them a solid choice in the treatment of high
cholesterol.
• Research shows that PCSK9 inhibitors are highly efficacious
in decreasing serum cholesterol levels demonstrating the
ability to decrease cholesterol levels by upwards of 50%.
• Authors indicate that the dose selection will likely be left to the
clinician. The benefit of selecting a high dose and titrating
down lies in the ability to quickly decrease cholesterol thereby
decreasing risk of cardiovascular disease.
• Ballantyne and Roth are in agreement that bi-monthly dosing
may be the most appropriate regimen as it results in a very
steady state of control of cholesterol versus the variability seen
with monthly dosing schedule.
• Given the consistent ability of the PCSK9 inhibitors to
significantly decrease LDL-C levels, it appears that this new
class of therapeutics will present an option for patients and
clinicians to better decrease significant cardiovascular disease
risk.
• It does not appear that PCSK9 inhibitors would be marketed
nor expected to replace traditional statin therapy at this time,
however they will likely present an option to clinicians who
have patients who are intolerant to statins, not adequately
controlled on max dose therapy, or who present with familial
hypercholesterolemia.

